Investor2014
14 minutes ago
If KarXT becomes Standard of Care (SoC), then a confirmatory trial with A3-71 in Schizophrenia would almost certainly allow SoC co-administration. Given that will also apply to the placebo cohort, the trial would be measuring any differential efficacy resulting from A3-71. Of course, as is always th